Tacrolimus Ointment for Atopic Dermatitis

Tacrolimus Ointment for Atopic Dermatitis

To the Editor: Ruzicka et al. (Sept. 18, 1997, issue) 1 reported that tacrolimus (FK 506) ointment is beneficial in the treatment of atopic dermatitis. It is remarkable that an immunosuppressant agent produced a significant improvement in the symptoms of an inflammatory disease after three days of t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 1998-12, Vol.339 (24), p.1788-1789
1. Verfasser: Marone, G
Format: Artikel
Sprache:eng
Schlagworte:
Anti-Inflammatory Agents - therapeutic use
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - immunology
Down-Regulation
Humans
Immunosuppressive Agents - therapeutic use
Lymphocyte Activation - drug effects
Receptors, IgE - drug effects
T-Lymphocytes - drug effects
Tacrolimus - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1789
container_issue 24
container_start_page 1788
container_title The New England journal of medicine
container_volume 339
creator Marone, G
description To the Editor: Ruzicka et al. (Sept. 18, 1997, issue) 1 reported that tacrolimus (FK 506) ointment is beneficial in the treatment of atopic dermatitis. It is remarkable that an immunosuppressant agent produced a significant improvement in the symptoms of an inflammatory disease after three days of treatment. I suggest that in this disorder, which is characterized by the activation of skin mast cells and infiltrating basophils, 2 tacrolimus acts as an antiinflammatory agent by modulating the release of inflammatory mediators. Mast cells and basophils act as both immunoregulators and proinflammatory cells through the release of vasoactive mediators and cytokines (e.g., interleukin-4). . . .
doi_str_mv 10.1056/NEJM199812103392415
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70075779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70073409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-f625a76ceabc4d93e6afbf6be46d2e545fa739ce359c1f309e54c2b2c44332873</originalsourceid><addsrcrecordid>eNqNkU1LAzEQhoMotVZ_gQiLB0FkNd_ZHEutX1R7qeeQTRPYstmtye7Bf9-UFg8i6lwGZp554Z0XgHMEbxFk_O5t-vKKpCwQRpAQiSliB2CIGCE5pZAfgiGEuMipkOQYnMS4gqkQlQMwkAUXjMkhuF5oE9q68n3M5lXTedt0mWtDNu7adWWyexu87qquiqfgyOk62rN9H4H3h-li8pTP5o_Pk_EsN5TDLnccMy24sbo0dCmJ5dqVjpeW8iW2jDKnBZHGEiYNcgTKNDO4xIZSQnAhyAhc7XTXof3obeyUr6Kxda0b2_ZRCQgFE8nTf0BC4Ra8_Aau2j40yYTCmEjGREH_hCjHRYLIDko_izFYp9ah8jp8KgTVNhP1Qybp6mIv3ZfeLr9u9iGk_c1u731UjV35X9U2zvaQfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223955784</pqid></control><display><type>article</type><title>Tacrolimus Ointment for Atopic Dermatitis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Marone, G</creator><creatorcontrib>Marone, G</creatorcontrib><description>To the Editor: Ruzicka et al. (Sept. 18, 1997, issue) 1 reported that tacrolimus (FK 506) ointment is beneficial in the treatment of atopic dermatitis. It is remarkable that an immunosuppressant agent produced a significant improvement in the symptoms of an inflammatory disease after three days of treatment. I suggest that in this disorder, which is characterized by the activation of skin mast cells and infiltrating basophils, 2 tacrolimus acts as an antiinflammatory agent by modulating the release of inflammatory mediators. Mast cells and basophils act as both immunoregulators and proinflammatory cells through the release of vasoactive mediators and cytokines (e.g., interleukin-4). . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199812103392415</identifier><identifier>PMID: 9867559</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Anti-Inflammatory Agents - therapeutic use ; Dermatitis, Atopic - drug therapy ; Dermatitis, Atopic - immunology ; Down-Regulation ; Humans ; Immunosuppressive Agents - therapeutic use ; Lymphocyte Activation - drug effects ; Receptors, IgE - drug effects ; T-Lymphocytes - drug effects ; Tacrolimus - therapeutic use</subject><ispartof>The New England journal of medicine, 1998-12, Vol.339 (24), p.1788-1789</ispartof><rights>Copyright © 1998 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts Dec 10 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-f625a76ceabc4d93e6afbf6be46d2e545fa739ce359c1f309e54c2b2c44332873</citedby><cites>FETCH-LOGICAL-c460t-f625a76ceabc4d93e6afbf6be46d2e545fa739ce359c1f309e54c2b2c44332873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199812103392415$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223955784?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2758,2759,26102,27923,27924,52381,54063,64384,64386,64388,72340</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9867559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marone, G</creatorcontrib><title>Tacrolimus Ointment for Atopic Dermatitis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor: Ruzicka et al. (Sept. 18, 1997, issue) 1 reported that tacrolimus (FK 506) ointment is beneficial in the treatment of atopic dermatitis. It is remarkable that an immunosuppressant agent produced a significant improvement in the symptoms of an inflammatory disease after three days of treatment. I suggest that in this disorder, which is characterized by the activation of skin mast cells and infiltrating basophils, 2 tacrolimus acts as an antiinflammatory agent by modulating the release of inflammatory mediators. Mast cells and basophils act as both immunoregulators and proinflammatory cells through the release of vasoactive mediators and cytokines (e.g., interleukin-4). . . .</description><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatitis, Atopic - immunology</subject><subject>Down-Regulation</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Receptors, IgE - drug effects</subject><subject>T-Lymphocytes - drug effects</subject><subject>Tacrolimus - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkU1LAzEQhoMotVZ_gQiLB0FkNd_ZHEutX1R7qeeQTRPYstmtye7Bf9-UFg8i6lwGZp554Z0XgHMEbxFk_O5t-vKKpCwQRpAQiSliB2CIGCE5pZAfgiGEuMipkOQYnMS4gqkQlQMwkAUXjMkhuF5oE9q68n3M5lXTedt0mWtDNu7adWWyexu87qquiqfgyOk62rN9H4H3h-li8pTP5o_Pk_EsN5TDLnccMy24sbo0dCmJ5dqVjpeW8iW2jDKnBZHGEiYNcgTKNDO4xIZSQnAhyAhc7XTXof3obeyUr6Kxda0b2_ZRCQgFE8nTf0BC4Ra8_Aau2j40yYTCmEjGREH_hCjHRYLIDko_izFYp9ah8jp8KgTVNhP1Qybp6mIv3ZfeLr9u9iGk_c1u731UjV35X9U2zvaQfg</recordid><startdate>19981210</startdate><enddate>19981210</enddate><creator>Marone, G</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K0Y</scope><scope>NAPCQ</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19981210</creationdate><title>Tacrolimus Ointment for Atopic Dermatitis</title><author>Marone, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-f625a76ceabc4d93e6afbf6be46d2e545fa739ce359c1f309e54c2b2c44332873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatitis, Atopic - immunology</topic><topic>Down-Regulation</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Receptors, IgE - drug effects</topic><topic>T-Lymphocytes - drug effects</topic><topic>Tacrolimus - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marone, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>New England Journal of Medicine</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marone, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tacrolimus Ointment for Atopic Dermatitis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1998-12-10</date><risdate>1998</risdate><volume>339</volume><issue>24</issue><spage>1788</spage><epage>1789</epage><pages>1788-1789</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>To the Editor: Ruzicka et al. (Sept. 18, 1997, issue) 1 reported that tacrolimus (FK 506) ointment is beneficial in the treatment of atopic dermatitis. It is remarkable that an immunosuppressant agent produced a significant improvement in the symptoms of an inflammatory disease after three days of treatment. I suggest that in this disorder, which is characterized by the activation of skin mast cells and infiltrating basophils, 2 tacrolimus acts as an antiinflammatory agent by modulating the release of inflammatory mediators. Mast cells and basophils act as both immunoregulators and proinflammatory cells through the release of vasoactive mediators and cytokines (e.g., interleukin-4). . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>9867559</pmid><doi>10.1056/NEJM199812103392415</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 1998-12, Vol.339 (24), p.1788-1789
issn 0028-4793
1533-4406
language eng
recordid cdi_proquest_miscellaneous_70075779
source MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine
subjects Anti-Inflammatory Agents - therapeutic use
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - immunology
Down-Regulation
Humans
Immunosuppressive Agents - therapeutic use
Lymphocyte Activation - drug effects
Receptors, IgE - drug effects
T-Lymphocytes - drug effects
Tacrolimus - therapeutic use
title Tacrolimus Ointment for Atopic Dermatitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T20%3A17%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tacrolimus%20Ointment%20for%20Atopic%20Dermatitis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Marone,%20G&rft.date=1998-12-10&rft.volume=339&rft.issue=24&rft.spage=1788&rft.epage=1789&rft.pages=1788-1789&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199812103392415&rft_dat=%3Cproquest_cross%3E70073409%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223955784&rft_id=info:pmid/9867559&rfr_iscdi=true